Nissay Asset Management Corp Japan ADV decreased its stake in shares of Baxter International Inc (NYSE:BAX) by 17.3% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 103,325 shares of the medical instruments supplier’s stock after selling 21,688 shares during the quarter. Nissay Asset Management Corp Japan ADV’s holdings in Baxter International were worth $7,965,000 at the end of the most recent reporting period.
A number of other institutional investors also recently added to or reduced their stakes in BAX. FMR LLC increased its position in Baxter International by 25.6% during the second quarter. FMR LLC now owns 28,637,027 shares of the medical instruments supplier’s stock worth $2,114,558,000 after buying an additional 5,845,720 shares in the last quarter. Voya Investment Management LLC increased its position in Baxter International by 411.6% during the second quarter. Voya Investment Management LLC now owns 3,411,849 shares of the medical instruments supplier’s stock worth $251,931,000 after buying an additional 2,745,012 shares in the last quarter. Morgan Stanley increased its position in Baxter International by 107.8% during the second quarter. Morgan Stanley now owns 2,873,253 shares of the medical instruments supplier’s stock worth $212,161,000 after buying an additional 1,490,287 shares in the last quarter. Standard Life Aberdeen plc increased its position in Baxter International by 77.2% during the second quarter. Standard Life Aberdeen plc now owns 2,596,870 shares of the medical instruments supplier’s stock worth $191,753,000 after buying an additional 1,131,691 shares in the last quarter. Finally, SPF Beheer BV purchased a new position in Baxter International during the second quarter worth $53,405,000. 83.08% of the stock is owned by institutional investors.
In related news, SVP Giuseppe Accogli sold 17,647 shares of Baxter International stock in a transaction on Monday, September 17th. The stock was sold at an average price of $77.27, for a total value of $1,363,583.69. Following the transaction, the senior vice president now owns 59,452 shares in the company, valued at $4,593,856.04. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Carole J. Shapazian sold 5,400 shares of Baxter International stock in a transaction on Wednesday, August 8th. The shares were sold at an average price of $72.97, for a total value of $394,038.00. Following the completion of the transaction, the director now owns 15,248 shares in the company, valued at approximately $1,112,646.56. The disclosure for this sale can be found here. 0.07% of the stock is owned by insiders.
Shares of NYSE:BAX opened at $68.66 on Wednesday. The firm has a market capitalization of $35.85 billion, a PE ratio of 27.69, a price-to-earnings-growth ratio of 1.81 and a beta of 0.77. The company has a quick ratio of 2.00, a current ratio of 2.62 and a debt-to-equity ratio of 0.39. Baxter International Inc has a 52 week low of $62.52 and a 52 week high of $78.38.
Baxter International (NYSE:BAX) last announced its quarterly earnings data on Wednesday, October 31st. The medical instruments supplier reported $0.80 EPS for the quarter, beating the Zacks’ consensus estimate of $0.74 by $0.06. The business had revenue of $2.77 billion during the quarter, compared to the consensus estimate of $2.79 billion. Baxter International had a return on equity of 16.63% and a net margin of 8.29%. The business’s revenue for the quarter was up 2.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.64 earnings per share. On average, research analysts anticipate that Baxter International Inc will post 2.98 earnings per share for the current fiscal year.
About Baxter International
Baxter International Inc provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. It offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.
Recommended Story: Diversification For Individual Investors
Want to see what other hedge funds are holding BAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Baxter International Inc (NYSE:BAX).
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.